These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Eddouzi J, Parker JE, Vale-Silva LA, Coste A, Ischer F, Kelly S, Manai M, Sanglard D. Antimicrob Agents Chemother; 2013 Jul; 57(7):3182-93. PubMed ID: 23629718 [Abstract] [Full Text] [Related]
3. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750 [Abstract] [Full Text] [Related]
7. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland. Szweda P, Gucwa K, Romanowska E, Dzierz Anowska-Fangrat K, Naumiuk Ł, Brillowska-Da Browska A, Wojciechowska-Koszko I, Milewski S. J Med Microbiol; 2015 Jun; 64(6):610-619. PubMed ID: 25818698 [Abstract] [Full Text] [Related]
10. A newly identified amino acid substitution T123I in the 14α-demethylase (Erg11p) of Candida albicans confers azole resistance. Wu Y, Gao N, Li C, Gao J, Ying C. FEMS Yeast Res; 2017 May 01; 17(3):. PubMed ID: 28334124 [Abstract] [Full Text] [Related]
14. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Antimicrob Agents Chemother; 1995 Nov 01; 39(11):2378-86. PubMed ID: 8585712 [Abstract] [Full Text] [Related]
17. Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans. Feng W, Yang J, Xi Z, Qiao Z, Lv Y, Wang Y, Ma Y, Wang Y, Cen W. Microb Drug Resist; 2017 Jul 01; 23(5):563-570. PubMed ID: 27976986 [Abstract] [Full Text] [Related]
18. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Holmes AR, Keniya MV, Ivnitski-Steele I, Monk BC, Lamping E, Sklar LA, Cannon RD. Antimicrob Agents Chemother; 2012 Mar 01; 56(3):1508-15. PubMed ID: 22203607 [Abstract] [Full Text] [Related]
19. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Diagn Microbiol Infect Dis; 2010 Apr 01; 66(4):373-84. PubMed ID: 20226328 [Abstract] [Full Text] [Related]
20. Voriconazole and multidrug resistance in Candida albicans. Wakieć R, Prasad R, Morschhäuser J, Barchiesi F, Borowski E, Milewski S. Mycoses; 2007 Mar 01; 50(2):109-15. PubMed ID: 17305773 [Abstract] [Full Text] [Related] Page: [Next] [New Search]